Recruiting

Exercise Program

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT06923397

Conditions

Lymphoma

Lymphoma, Hodgkin

Lymphoma, Non-Hodgkin

Sedentary Behavior

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Interrupted Sedentary Time Intervention

Study Details

Brief summary:

This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.

Conditions

Lymphoma

Lymphoma, Hodgkin

Lymphoma, Non-Hodgkin

Sedentary Behavior

Study ID

NCT06923397

Start date

Jun 5, 2025

Status verified date

Apr, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Nov 28, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
  • Patients diagnosed with lymphoma.
  • Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.
  • Aged ≥18 years; due to the rarity of the disease in those <18 years, this age bracket will not be included.
  • Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.
  • Have physician clearance to participate in exercise.
  • Speak English.
  • Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.
  • Access to a phone that can receive text messages.

Exclusion Criteria:

  • Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.
  • Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.
  • Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.
  • Patients currently taking weight loss drugs.
  • Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.
  • Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.

Study Design

Enrollment

24 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Interrupted Sedentary Time Intervention

The first 3 participants enrolled with be placed into the intervention group. After this, participants will be randomized in a group allocation ratio of 2:1 using permuted blocked design with varying block size and stratified by treatment plan. 14 participants will complete:

  • Baseline visit
  • Standard of care chemotherapy treatment regimen
  • Daily exercise sessions in-clinic up to 4x weekly and at home 6 days per week
  • Week 14 post-intervention visit

no intervention: Usual Care Control Group

Participants will be randomized in a group allocation ratio of 2:1 using permuted blocked design with varying block size and stratified by treatment plan. 7 participants will complete:

  • Baseline visit
  • Standard of Care chemotherapy treatment regimen
  • Week 14 visit
  • Participants will be offered Fitbit activity tracker and resistance bands at the end of the study.

Interventions

Interrupted Sedentary Time Intervention

A 12-week, semi-supervised exercise intervention comprised of reminder prompts, counseling, and activities of walking, cycling, and resistance band exercise for at-home and in-clinic settings. Supervision will be under an exercise trainer. Resistance bands, Libre Pro continuous blood sugar monitor, and Fitbit and ActivPAL trackers will be provided to participants.

Primary outcome measure

  • Intervention Completion Rate (Feasibility) [ Time Frame: 12 weeks ]
  • Refusal Rate [ Time Frame: 12 weeks ]
  • Retention Rate [ Time Frame: 13 weeks ]
  • Acceptability of Intervention Measure (AIM) Scale [ Time Frame: 13 weeks ]
  • Acceptability Exit Survey [ Time Frame: 13 weeks ]

Central Contacts and Locations

Central contacts

Christina Dieli-Conwright, MD, PhD

617-582-8321ChristinaM_Dieli-Conwright@dfci.harvard.edu

Locations

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Christina Dieli-Conwright, MD, PhD

617-582-8321ChristinaM_Dieli-Conwright@dfci.harvard.edu

Principal Investigator:

Christina Dieli-Conwright, MD, PhD

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Apr 13, 2026

Last verified

Apr, 2026

Keywords

  • Lymphoma
  • Hodgkin Lymphoma
  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin
  • Non-Hodgkin Lymphoma
  • Sedentary Behavior

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-04-13.